Table 2

Efficacy and ADRs to the 105 exposures to biologics prescribed for relapsing polychondritis in 41 patients

Exposures to biologicsResponse achieved during the first 6  months , n (%)CR achieved during the first 6  months , n (%)Variation in CS dose at M6, mg PEQ, median (range)*Follow-up, months, median (range)Discontinuation of biologic
Overall 
n (%)
Insufficient efficacy 
n (%)
Loss of efficacy 
n (%)
ADR 
n (%)
Stable 
CR
Overall (n=105)66 (62.9)20 (19.0)−5.0 (−72.5;+70.0)6.0 (0.1–80.8)77 (73.3)36 (34.3)19 (18.1)22 (20.9)1 (0.9)
TNF antagonists (n=60)38 (63.3)14 (23.3)−5 (−53;+70)6.0 (0.4–80.8)47 (78.3)23 (38.3)15 (25.0)8 (13.3)1 (1.7)
 Infliximab (n=20)12 (60.0)7 (35.0)−5 (−50;+70)6.5 (0.4–80.8)16 (80.0)7 (35.0)6 (30.0)3 (15.0)0
 Adalimumab (n=25)16 (64.0)5 (20.0)−7.5 (−53;+10)8.0 (0.4–71.7)18 (72.0)6 (24.0)7 (28.0)5 (20.0)1 (4.0)
 Etanercept (n=11)8 (72.7)0−5 (−50;+0)5.5 (0.7–36.7)11 (100)8 (72.7)2 (18.2)2 (18.2)0
 Golimumab (n=3)2 (66.7)2 (66.7)−203.8 (3.4–7.2)1 (33.3)1 (33.3)000
 Certolizumab (n=1)002.91 (100)1 (100)01 (100)0
Tocilizumab (n=17)12 (70.6)2 (11.8)−1 (−72.5;+0)3.7 (0.4–36.2)10 (58.8)4 (23.5)2 (11.7)4 (23.5)0
Anakinra (n=15)8 (53.3)2 (13.3)−12.5 (-20;+0)2.6 (0.3–63.8)13 (86.7)5 (33.3)07 (46.7)0
Rituximab (n=7)5 (71.4)1 (14.3)−3 (−30;+5)6.03 (42.8)3 (42.8)000
Abatacept (n=6)3 (50.0)1 (16.7)−16 (−40;+0)9.5 (0.1–37.1)6 (100)3 (50.0)2 (33.3)1 (16.7)0
  • *Data available for 13 patients on infliximab, 16 on adalimumab, 7 on etanercept, 1 on golimumab, none on certolizumab pegol, 4 on anakinra, 7 on rituximab, 10 on tocilizumab and 4 on abatacept.

  • ADR, adverse drug reaction; CR, complete response; CS, corticosteroids; PEQ, prednisone equivalent; TNF, tumour necrosis factor.